Detailed description page of B3Pdb
This page provides detail information of Selected ID b3pdb_0150 |
Primary information | |
---|---|
B3PDB ID | b3pdb_0150 |
Peptide Name | MMP-2200 |
PEPTIDE SEQUENCE (1-letter) | Y-D-TGFLS(β-O-Glc)-CONH2 |
PEPTIDE SEQUENCE (3-letter) | Tyr-D-Thr-Gly-Phe-Leu-Ser(β-O-Glc)-CONH2 |
N-terminal modification | NA |
C-terminal modification | NA |
Chemical modification | Glycosylated serine residue |
Peptide Length | 6 |
Conformation | Linear |
Peptide Nature | NA |
Source/Origin of peptide | Chemically synthesized |
SMILES | NA |
Cell Line | NA |
In vitro CONCENTRATION | NA |
In vitro METHOD | NA |
In vitro RESULT | NA |
ANIMAL MODEL | Adult Sprague-Dawley rats |
In vivo CONCENTRATION | 10mg/Kg |
In vivo MODE OF DELIVERY | Intraperitoneal |
In vivo METHOD | Microdialysis analysis and LCMS analysis |
In vivo RESULT | Significant amount of peptide crosses blood brain barrier after 12 minute and remain stable up to 80 |
ACTION | Shows potent analgesic behaviour |
TRANSPORT TYPE | NA |
SUBCELLULAR LOCALISATION | NA |
COMBINATION | NA |
PHYSICAL CONDITION | Parkinson |
RESPONSE | Stability/half life |
RESULT | 80 minute |
LABEL | NA |
PMID | 23127847 |